Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Top 5 Marijuana Stocks for 2019
With individual stock selection now more critical than ever, this report is designed to bring you some of our top ideas in the marijuana industry this year.
One of the companies highlighted in this report offers a life-changing therapy that reduces the number of seizures in children with two rare types of childhood-onset epilepsy. It has the potential for the stock to sky-rocket. You need to find out the name of this company before the rest of the market does.
P.S. Not many retail investors pay attention to the marijuana sector. Use this complimentary guide and get a head start on your path to profiting from the booming cannabis industry!
Menu

Nuvectra Corp Cmn ST (NVTR)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 175,607
  • Shares Outstanding, K 17,792
  • Annual Sales, $ 48,830 K
  • Annual Income, $ -48,130 K
  • 60-Month Beta -0.04
  • Price/Sales 3.56
  • Price/Cash Flow N/A
  • Price/Book 1.85

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/19
See More
  • Average Estimate -0.65
  • Number of Estimates 2
  • High Estimate -0.62
  • Low Estimate -0.68
  • Prior Year -0.84
  • Growth Rate Est. (year over year) +22.62%

Price Performance

See More
Period Period Low Period High Performance
1-Month
9.50 +3.89%
on 04/22/19
12.52 -21.20%
on 03/25/19
-1.77 (-15.21%)
since 03/22/19
3-Month
9.50 +3.89%
on 04/22/19
14.75 -33.08%
on 01/25/19
-4.05 (-29.09%)
since 01/23/19
52-Week
9.50 +3.89%
on 04/22/19
25.17 -60.79%
on 10/04/18
-3.61 (-26.78%)
since 04/23/18

Most Recent Stories

More News
Nuvectra to Report First Quarter 2019 Financial Results on May 1, 2019

Nuvectra Corporation (NASDAQ: NVTR), a neurostimulation medical device company, announced today that it will release its financial results for the first quarter ended March 31, 2019 on Wednesday, May 1,...

NVTR : 9.80 (-0.71%)
Recent Analysis Shows Nuvectra, Red Lion Hotels, Rave Restaurant Group, Aeglea BioTherapeutics, CPI Aerostructures, and Qumu Market Influences -- Renewed Outlook, Key Drivers of Growth

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Nuvectra Corporation (NASDAQ:NVTR),...

AGLE : 7.44 (+0.13%)
NVTR : 9.80 (-0.71%)
CVU : 6.43 (-0.16%)
RAVE : 1.44 (-0.69%)
QUMU : 2.98 (+2.76%)
RLH : 8.20 (-1.80%)
Nuvectra(R) Appoints Anthony P. Bihl, III as New Chairman of the Board

Nuvectra Corporation (NASDAQ: NVTR), a neurostimulation medical device company, today announced the appointment of Anthony P. Bihl, III as Chairman of the Board of Directors, following Dr. Joseph A. Miller's...

NVTR : 9.80 (-0.71%)
Nuvectra(R) Reports Fourth Quarter and Full Year 2018 Financial Results

Nuvectra Corporation (NASDAQ: NVTR), a neurostimulation medical device company, announced today financial results for the fourth quarter and full year ended December 31, 2018.

NVTR : 9.80 (-0.71%)
Nuvectra(R) to Present at 39th Annual Cowen Healthcare Conference

Nuvectra Corporation (NASDAQ: NVTR), a neurostimulation medical device company, announced today that Fred Parks, PhD, Chief Executive Officer, and Walter Berger, Chief Operating Officer & Chief Financial...

NVTR : 9.80 (-0.71%)
The Future Is Now; Med Tech That's Changing Lives

Investorideas.com, a leading investor news resource covering medical technology and healthcare stocks releases a snapshot looking at the rapid advancements happening in the med tech sector and how many...

NVTR : 9.80 (-0.71%)
BSX : 35.05 (-2.34%)
BSGM : 6.43 (-0.31%)
IRTC : 71.32 (+0.13%)
Nuvectra to Report Fourth Quarter and Full Year 2018 Financial Results on February 28, 2019

Nuvectra Corporation (NASDAQ: NVTR), a neurostimulation medical device company, announced today that it will release its financial results for the fourth quarter and full year ended December 31, 2018 on...

NVTR : 9.80 (-0.71%)
Nuvectra(R) Appoints Dr. Fred B. Parks as Chief Executive Officer

Nuvectra Corporation (NASDAQ: NVTR), a neurostimulation medical device company, today announced the appointment of Fred B. Parks, PhD, as Chief Executive Officer, effective immediately. Dr. Parks has served...

NVTR : 9.80 (-0.71%)
Nuvectra Provides Update on Virtis(TM) FDA PMA Submission

Nuvectra Corporation (NASDAQ: NVTR), a medical device company dedicated to neuromodulation, announced today that the U.S. Food and Drug Administration (FDA) has advised that its review of Company's pre-market...

NVTR : 9.80 (-0.71%)
Nuvectra(R) Announces Preliminary Unaudited Fourth Quarter and Full Year 2018 Revenue

Nuvectra Corporation (NASDAQ: NVTR), a neurostimulation medical device company, announced today preliminary unaudited revenue for the fourth quarter and full year ended December 31, 2018.

NVTR : 9.80 (-0.71%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 96% Sell with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Trade NVTR with:

Business Summary

Nuvectra Corporation develops and commercializes neuromodulation medical device for the treatment of nervous system disorders. It also provides neural interface technology, components and systems, as well as NeuroNexus SmartBox portable control and data streaming systems. Nuvectra Corporation is based...

See More

Key Turning Points

2nd Resistance Point 10.30
1st Resistance Point 10.08
Last Price 9.80
1st Support Level 9.69
2nd Support Level 9.52

See More

52-Week High 25.17
Fibonacci 61.8% 19.18
Fibonacci 50% 17.33
Fibonacci 38.2% 15.49
Last Price 9.80
52-Week Low 9.50

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar